Log inSign up
user avatar
Genprex, Inc.
@genprex
Genprex (Nasdaq: $GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes.
Austin, TX
genprex.com
Joined July 2016
504
Following
2,305
Followers
  • user avatar
    Genprex, Inc.
    @genprex
    Jan 21, 2020
    Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer zpr.io/tAfit $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Jan 3, 2022
    Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination with Keytruda® for the Treatment of Non-Small Cell Lung Cancer zpr.io/TXYnriHWSLTr $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Mar 2, 2022
    Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer zpr.io/dsj9Kumptupv $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Jan 21, 2019
    According to @theNCI, #lungcancer is the leading cause of #cancer deaths in the US, killing more people than breast, colon, kidney, liver and prostate cancers combined via @statnews bit.ly/2SUL9aj
  • user avatar
    Genprex, Inc.
    @genprex
    Jan 4, 2022
    Genprex's CEO Rodney Varner talks with Proactive about the company's recent FDA Fast Track Designation for its Acclaim-2 patient population. Watch the interview here: bit.ly/3q2xsJH
  • user avatar
    Genprex, Inc.
    @genprex
    Jun 28, 2023
    Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer genprex.com/news/genprex-r… $GNPX
    726
  • user avatar
    Genprex, Inc.
    @genprex
    Feb 20, 2023
    Preclinical data highlighting the therapeutic potential of Genprex’s #genetherapy for Type 1 #diabetes will be presented at #ATTD2023 on Feb. 25 in Berlin
    1.9K
  • user avatar
    Genprex, Inc.
    @genprex
    May 5, 2020
    Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies zpr.io/tcGRF $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Jan 27, 2022
    Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer zpr.io/hRrM2dE6kNSL $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Feb 26, 2021
    Dr. George Gittes, the inventor of the diabetes gene therapy, GPX-002, discusses paradigm shifts in diabetes and pediatric medicine with Progress, Potential, and Possibilities’ Ira S. Pastor. $GNPX Watch the video: genprex.com/videos/dr-geor…
  • user avatar
    Genprex, Inc.
    @genprex
    Mar 31, 2022
    Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer zpr.io/yFWn9VrbukKW $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Feb 8, 2021
    Genprex Announces Formation of Clinical Advisory Board zpr.io/RtqAS $GNPX
  • user avatar
    Genprex, Inc.
    @genprex
    Apr 2, 2021
    This article in Cancer World cites Genprex as having the most advanced gene therapy delivery system. Read more about our ONCOPREX Nanoparticle Delivery System in this article, "Can gene therapy be made to work against solid tumors?" bit.ly/3cLFr7j
  • user avatar
    Genprex, Inc.
    @genprex
    Jun 12, 2019
    Best of luck to our newest intern, Jim, who's participating in the #InternBattle tomorrow representing Genprex! Good luck Jim #BattleoftheInterns @MassTLC